


Budesonide

Cat. No.:	HY-13580
CAS No.:	51333-22-3
Molecular Formula:	C ₂₅ H ₃₄ O ₆
Molecular Weight:	430.53
Target:	Glucocorticoid Receptor
Pathway:	Immunology/Inflammation; Vitamin D Related/Nuclear Receptor
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 215 mg/mL (499.38 mM; Need ultrasonic and warming)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.3227 mL	11.6136 mL	23.2272 mL
		5 mM	0.4645 mL	2.3227 mL	4.6454 mL
10 mM		0.2323 mL	1.1614 mL	2.3227 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.83 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.83 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.83 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Budesonide, an inhaled glucocorticoid steroid, is an orally active glucocorticoid receptor agonist. Budesonide decreases the size of lung tumors, reverses DNA hypomethylation and modulates mRNA expression of genes. Budesonide is an anti-inflammatory agent used for asthma ^{[1][2][3]} .
In Vitro	Budesonide is selective for human glucocorticoid receptor (hGR; EC ₅₀ =45.7 pM) over mineralocorticoid receptors (EC ₅₀ =7,620 pM) in CV-1 cells ^[1] . Budesonide (30 min prior to LPS) suppresses the activation of the NLRP3 inflammasome by LPS (100 ng/mL) plus ATP (5 mM)

in macrophages (RAW 264.7 cells)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Budesonide (2.0 mg/kg; orally via their diet; at 2, 7 and 21 days prior to killing) decreases the size of lung tumors^[3].

Budesonide (0.5 mg/kg; intranasal administration 1 h before LPS injection (5 mg/kg)) pretreatment dramatically attenuates pathological injury and reduces pathological scores in mice with ALI in adult male C57BL/6 mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female strain A/J mice at 8 weeks of age ^[3]
Dosage:	2.0 mg/kg
Administration:	Orally via their diet; at 2, 7 and 21 days prior to killing (27 weeks)
Result:	Reduced the size of the lung tumors after 2 days and rapidly decreased the size of lung tumors, reversed DNA hypomethylation and modulated mRNA expression of genes.

CUSTOMER VALIDATION

- Mil Med Res. 2022 Jan 29;9(1):7.
- J Control Release. 2019 Dec 28;316:66-78.
- Drug Test Anal. 2020 Aug 27.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Claudia Grossmann, et al. Transactivation via the Human Glucocorticoid and Mineralocorticoid Receptor by Therapeutically Used Steroids in CV-1 Cells: A Comparison of Their Glucocorticoid and Mineralocorticoid Properties. Eur J Endocrinol. 2004 Sep;151(3):

[2]. Liang Dong, et al. Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice. J Imm

[3]. Michael A Pereira, et al. Modulation by Budesonide of DNA Methylation and mRNA Expression in Mouse Lung Tumors. Int J Cancer. 2007 Mar 1;120(5):1150-3.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA